Neoplasia following use of BMPs: Is there an increased risk?

Expert Opinion on Drug Safety

Volumn 13, Issue 11, 2014, Pages 1525-1534

  Pountos, Ippokratis ^a   Panteli, Michalis ^a   Georgouli, Theodora ^a   Giannoudis, Peter V ^b  

^a UNIVERSITY OF LEEDS   (United Kingdom)

^b UNIVERSITY OF LEEDS   (United Kingdom)

Author keywords

Bone healing; Bone morphogenetic proteins; Carcinogenesis; Mesenchymal stem cells; Neoplasia

Indexed keywords

BONE MORPHOGENETIC PROTEIN; BONE MORPHOGENETIC PROTEIN 10; BONE MORPHOGENETIC PROTEIN 11; BONE MORPHOGENETIC PROTEIN 12; BONE MORPHOGENETIC PROTEIN 14; BONE MORPHOGENETIC PROTEIN 15; BONE MORPHOGENETIC PROTEIN 2; BONE MORPHOGENETIC PROTEIN 4; BONE MORPHOGENETIC PROTEIN 5; BONE MORPHOGENETIC PROTEIN 6; BONE MORPHOGENETIC PROTEIN 9; GROWTH DIFFERENTIATION FACTOR 6; OSTEOGENIC PROTEIN 1; OSTEOGENIC PROTEIN 8; OSTEOGENIN; PROCOLLAGEN C PROTEINASE; UNCLASSIFIED DRUG;

ARTICLE; AUTOGRAFT; BONE CANCER; BONE MALFORMATION; BREAST CANCER; CANCER INCIDENCE; CANCER PROGNOSIS; CANCER RISK; CANCER SUSCEPTIBILITY; CARCINOGENESIS; CLINICAL STUDY; COLORECTAL CANCER; DRUG MEGADOSE; DYSPHAGIA; DYSPNEA; EXPERIMENTAL STUDY; GERMLINE MUTATION; HETEROTOPIC OSSIFICATION; HUMAN; HYPOTHESIS; IN VITRO STUDY; IN VIVO STUDY; INFLAMMATION; KIDNEY FAILURE; LUNG CANCER; METASTASIS; NEOPLASM; NEUROLOGIC DISEASE; NONHUMAN; OFF LABEL DRUG USE; OSTEOLYSIS; OSTEOSARCOMA; PATIENT SAFETY; POSTOPERATIVE EDEMA; PROSTATE CANCER; TIBIA FRACTURE; TIBIAL PLATEAU FRACTURE; URINARY TRACT DISEASE; ANIMAL; BONE REGENERATION; CELL TRANSFORMATION; CHEMICALLY INDUCED; DRUG EFFECTS; FRACTURE HEALING; METABOLISM; NEOPLASMS; PATHOLOGY; RISK ASSESSMENT; RISK FACTOR; SIGNAL TRANSDUCTION;

ANIMALS; BONE MORPHOGENETIC PROTEINS; BONE REGENERATION; CELL TRANSFORMATION, NEOPLASTIC; FRACTURE HEALING; HUMANS; NEOPLASMS; PATIENT SAFETY; RISK ASSESSMENT; RISK FACTORS; SIGNAL TRANSDUCTION;

EID: 84914671146     PISSN: 14740338     EISSN: 1744764X     Source Type: Journal    
DOI: 10.1517/14740338.2014.968124     Document Type: Article

References (75)

1. Senn N. Senn on the healing of aseptic bone cavities by implantation of antiseptic decalcified bone. Ann Surg 1889;10:352-68
2. Urist MR. Bone: formation by autoinduction. Science 1965;150:893-9
3. Friedenstein AJ, Gorskaja JF, Kulagina NN. Fibroblast precursors in normal and irradiated mouse hematopoietic organs. Exp Hematol 1976;4:267-74
4. Hernigou P, Homma Y. Tissue bioengineering in orthopedics. Clin Cases Miner Bone Metab 2012;9:21-3
5. Goujon E. Recherches experimentales sur les propriétes du tissu osseux. J L Anat 1869;6:399-412
6. Pountos I, Giannoudis PV. Biology of mesenchymal stem cells. Injury 2005;36(Suppl 3):S8-S12
7. Cao X, Chen D. The BMP signaling and in vivo bone formation. Gene 2005;357:1-8
8. Miyazono K, Maeda S, Imamura T. BMP receptor signaling: transcriptional targets, regulation of signals, and signaling cross-talk. Cytokine Growth Factor Rev 2005;16:251-63
9. Ye L, Lewis-Russell JM, Kyanaston HG, Jiang WG. Bone morphogenetic proteins and their receptor signaling in prostate cancer. Histol Histopathol 2007;22:1129-47
10. Hsu MY, Rovinsky S, Penmatcha S, et al. Bone morphogenetic proteins in melanoma: angel or devil? Cancer Metastasis Rev 2005;24:251-63
11. Zhang H, Bradley A. Mice deficient for BMP2 are nonviable and have defects in amnion/chorion and cardiac development. Development 1996;122(10):2977-86
12. Carreira AC, Lojudice FH, Halcsik E, et al. Bone morphogenetic proteins: facts, challenges, and future perspectives. J Dent Res 2014;93(4):335-45
13. Bragdon B, Moseychuk O, Saldanha S, et al. Bone morphogenetic proteins: a critical review. Cell Signal 2011;23:609-20
14. Bandyopadhyay A, Yadav PS, Prashar P. BMP signaling in development and diseases: a pharmacological perspective. Biochem Pharmacol 2013;85:857-64
15. Cai J, Pardali E, Sánchez-Duffhues G, ten Dijke P. BMP signaling in vascular diseases. FEBS Lett 2012;586:1993-2002
16. Canalis E, Economides AN, Gazzerro E. Bone morphogenetic proteins, their antagonists, and the skeleton. Endocr Rev 2003;24:218-35
17. Hogan BL. Bone morphogenetic proteins in development. Curr Opin Genet Dev 1996;6:432-8
18. Kallioniemi A. Bone morphogenetic protein 4-a fascinating regulator of cancer cell behavior. Cancer Genet 2012;205:267-77
19. Jain AP, Pundir S, Sharma A. Bone morphogenetic proteins: the anomalous molecules. J Indian Soc Periodontol 2013;17:583-6
20. Pountos I, Georgouli T, Henshaw K, et al. The effect of bone morphogenetic protein-2, bone morphogenetic protein-7, parathyroid hormone, and plateletderived growth factor on the proliferation and osteogenic differentiation of mesenchymal stem cells derived from osteoporotic bone. J Orthop Trauma 2010;24:552-6
21. Wan M, Cao X. BMP signaling in skeletal development. Biochem Biophys Res Commun 2005;328:651-7
22. Kanakaris NK, Paliobeis C, Nlanidakis N, Giannoudis PV. Biological enhancement of tibial diaphyseal aseptic non-unions: the efficacy of autologous bone grafting, BMPs and reaming by-products. Injury 2007;38(Suppl 2):S65-75
23. Friedlaender GE, Perry CR, Cole JD, et al. Osteogenic protein-1 (bone morphogenetic protein-7) in the treatment of tibial nonunions. J Bone Joint Surg Am 2001;83-A:S151-8
24. Zimmermann G, Wagner C, Schmeckenbecher K, et al. Treatment of tibial shaft non-unions: bone morphogenetic proteins versus autologous bone graft. Injury 2009;40(Suppl 3):S50-3
25. Blokhuis TJ, Calori GM, Schmidmaier G. Autograft versus BMPs for the treatment of non-unions: what is the evidence? Injury 2013;44(Suppl 1):S40-2
26. Ong KL, Villarraga ML, Lau E, et al. Off-label use of bone morphogenetic proteins in the United States using administrative data. Spine (Phila Pa 1976) 2010;35:1794-800
27. Lad SP, Bagley JH, Karikari IO, et al. Cancer after spinal fusion: the role of bone morphogenetic protein. Neurosurgery 2013;73(3):440-9
28. Cooper GS, Kou TD. Risk of cancer after lumbar fusion surgery with recombinant human bone morphogenic protein-2 (rh-BMP-2). Spine (Phila Pa 1976) 2013;38:1862-8
29. Dimar JR II, Glassman SD, Burkus JK, et al. Clinical and radiographic analysis of an optimized rhBMP-2 formulation as an autograft replacement in posterolateral lumbar spine arthrodesis. J Bone Joint Surg Am 2009;91:1377-86
30. Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. BMJ 2009;339:b2535
31. Mines D, Gu Y, Kou TD, Cooper GS. Recombinant human bone morphogenetic protein-2 and pancreatic cancer: a retrospective cohort study. Pharmacoepidemiol Drug Saf 2011;20(2):111-18
32. Vaccaro AR, Whang PG, Patel T, et al. The safety and efficacy of OP-1 (rhBMP-7) as a replacement for iliac crest autograft for posterolateral lumbar arthrodesis: minimum 4-year follow-up of a pilot study. Spine J 2008;8:457-65
33. Carragee EJ, Chu G, Rohatgi R, et al. Cancer risk after use of recombinant bone morphogenetic protein-2 for spinal arthrodesis. J Bone Joint Surg Am 2013;95:1537-45
34. Mesfin A, Buchowski JM, Zebala LP, et al. High-dose rhBMP-2 for adults: major and minor complications: a study of 502 spine cases. J Bone Joint Surg Am 2013;95:1546-53
35. Latzman JM, Kong L, Liu C, Samadani U. Administration of human recombinant bone morphogenetic protein-2 for spine fusion may be associated with transient postoperative renal insufficiency. Spine (Phila Pa 1976) 2010;35:E231-7
36. Simmonds MC, Brown JV, Heirs MK, et al. Safety and effectiveness of recombinant human bone morphogenetic protein-2 for spinal fusion: a metaanalysis of individual-participant data. Ann Intern Med 2013;158:877-89
37. Delawi D, Dhert WJ, Rillardon L, et al. A prospective, randomized, controlled, multicenter study of osteogenic protein-1 in instrumented posterolateral fusions: report on safety and feasibility. Spine (Phila Pa 1976) 2010;35:1185-91
38. Fu R, Selph S, McDonagh M, et al. Effectiveness and harms of recombinant human bone morphogenetic protein-2 in spine fusion: a systematic review and meta-analysis. Ann Intern Med 2013;158:890-902
39. Food and Drug Administration (FDA). Summary of safety and effectiveness data. 2002. Available from: http://www.accessdata.fda.gov/cdrh-docs/pdf/p000058b.pdf
40. Woo EJ. Recombinant human bone morphogenetic protein-2: adverse events reported to the Manufacturer and User Facility Device Experience database. Spine J 2012;12:894-9
41. De Bosscher K, Hill CS, Nicolás FJ. Molecular and functional consequences of Smad4 C-terminal missense mutations in colorectal tumour cells. Biochem J 2004;379:209-16
42. Zhou XP, Woodford-Richens K, Lehtonen R, et al. Germline mutations in BMPR1A/ALK3 cause a subset of cases of juvenile polyposis syndrome and of Cowden and Bannayan-Riley-Ruvalcaba syndromes. Am J Hum Genet 2001;69:704-11
43. Lubbe SJ, Pittman AM, Matijssen C, et al. Evaluation of germline BMP4 mutation as a cause of colorectal cancer. Hum Mutat 2011;32:E1928-38
44. Wang L, Park P, La Marca F, et al. Bone formation induced by BMP-2 in human osteosarcoma cells. Int J Oncol 2013;43:1095-102
45. Yang X, Wang YP, Liu FX, et al. Increased invasiveness of osteosarcoma mesenchymal stem cells induced by bone-morphogenetic protein-2. In vitro Cell Dev Biol Anim 2013;49:270-8
46. Yoshikawa H, Nakase T, Myoui A, Ueda T. Bone morphogenetic proteins in bone tumors. J Orthop Sci 2004;9:334-40
47. Weiss KR, Cooper GM, Jadlowiec JA, et al. VEGF and BMP expression in mouse osteosarcoma cells. Clin Orthop Relat Res 2006;450:111-17
48. Langenfeld EM, Calvano SE, Abou-Nukta F, et al. The mature bone morphogenetic protein-2 is aberrantly expressed in non-small cell lung carcinomas and stimulates tumor growth of A549 cells. Carcinogenesis 2003;24(9):1445-54
49. Langenfeld EM, Langenfeld J. Bone morphogenetic protein-2 stimulates angiogenesis in developing tumors. Mol Cancer Res 2004;2(3):141-9
50. Singh A, Morris RJ. The Yin and Yang of bone morphogenetic proteins in cancer. Cytokine Growth Factor Rev 2010;21:299-313
51. Dai J, Kitagawa Y, Zhang J, et al. Vascular endothelial growth factor contributes to the prostate cancerinduced osteoblast differentiation mediated by bone morphogenetic protein. Cancer Res 2004;64:994-9
52. Buijs JT, Henriquez NV, van Overveld PG, et al. Bone morphogenetic protein 7 in the development and treatment of bone metastases from breast cancer. Cancer Res 2007;67:8742-51
53. Masuda H, Fukabori Y, Nakano K, et al. Increased expression of bone morphogenetic protein-7 in bone metastatic prostate cancer. Prostate 2003;54:268-74
54. Miyazaki H, Watabe T, Kitamura T, Miyazono K. BMP signals inhibit proliferation and in vivo tumor growth of androgen-insensitive prostate carcinoma cells. Oncogene 2004;23:9326-35
55. Buijs JT, Rentsch CA, van der Horst G, et al. BMP7, a putative regulator of epithelial homeostasis in the human prostate, is a potent inhibitor of prostate cancer bone metastasis in vivo. Am J Pathol 2007;171:1047-57
56. Virtanen S, Alarmo EL, Sandström S, et al. Bone morphogenetic protein -4 and -5 in pancreatic cancer - novel bidirectional players. Exp Cell Res 2011;317:2136-46
57. Clement JH, Raida M, Sänger J, et al. Bone morphogenetic protein 2 (BMP-2) induces in vitro invasion and in vivo hormone independent growth of breast carcinoma cells. Int J Oncol 2005;27:401-7
58. Ye L, Bokobza SM, Jiang WG. Bone morphogenetic proteins in development and progression of breast cancer and therapeutic potential (review). Int J Mol Med 2009;24:591-7
59. Deng H, Makizumi R, Ravikumar TS, et al. Bone morphogenetic protein-4 is overexpressed in colonic adenocarcinomas and promotes migration and invasion of HCT116 cells. Exp Cell Res 2007;313:1033-44
60. Hardwick JC, Kodach LL, Offerhaus GJ, van den Brink GR. Bone morphogenetic protein signalling in colorectal cancer. Nat Rev Cancer 2008;8:806-12
61. Lorente-Trigos A, Varnat F, Melotti A, Ruiz i Altaba A. BMP signalling promotes the growth of primary human colon carcinomas in vivo. J Mol Cell Biol 2010;2:318-32
62. Smucker JD, Rhee JM, Singh K, et al. Increased swelling complications associated with off-label usage of rhBMP-2 in the anterior cervical spine. Spine (Phila Pa 1976) 2006;31:2813-19
63. INFUSE Bone graft package insert. Available from: https://www.infusebonegraft.com/spine-package-insert.pdf
64. FDA Public Health Notification: lifethreatening Complications Associated with Recombinant Human Bone Morphogenetic Protein in Cervical Spine Fusion. Available from: http://www.fda.gov/MedicalDevices/Safety/AlertsandNotices/PublicHealthNotifications/ucm062000.htm
65. Boraiah S, Paul O, Hawkes D, et al. Complications of recombinant human BMP-2 for treating complex tibial plateau fractures: a preliminary report. Clin Orthop Relat Res 2009;467:3257-62
66. Ritting AW, Weber EW, Lee MC. Exaggerated inflammatory response and bony resorption from BMP-2 use in a pediatric forearm nonunion. J Hand Surg Am 2012;37:316-21
67. Axelrad TW, Steen B, Lowenberg DW, et al. Heterotopic ossification after the use of commercially available recombinant human bone morphogenetic proteins in four patients. J Bone Joint Surg Br 2008;90:1617-22
68. Vaccaro AR, Lawrence JP, Patel T, et al. The safety and efficacy of OP-1 (rhBMP-7) as a replacement for iliac crest autograft in posterolateral lumbar arthrodesis: a long-term (>4 years) pivotal study. Spine (Phila Pa 1976) 2008;33:2850-62
69. Baskin DS, Ryan P, Sonntag V, et al. A prospective, randomized, controlled cervical fusion study using recombinant human bone morphogenetic protein-2 with the CORNERSTONE-SR allograft ring and the ATLANTIS anterior cervical plate. Spine (Phila Pa 1976) 2003;28:1219-24
70. Kanakaris NK, Calori GM, Verdonk R, et al. Application of BMP-7 to tibial non-unions: a 3-year multicenter experience. Injury 2008;39(Suppl 2):S83-90
71. Senta H, Park H, Bergeron E, et al. Cell responses to bone morphogenetic proteins and peptides derived from them: biomedical applications and limitations. Cytokine Growth Factor Rev 2009;20(3):213-22
72. Dahabreh Z, Calori GM, Kanakaris NK, et al. A cost analysis of treatment of tibial fracture nonunion by bone grafting or bone morphogenetic protein-7. Int Orthop 2009;33:1407-14
73. Schmidmaier G, Schwabe P, Strobel C, Wildemann B. Carrier systems and application of growth factors in orthopaedics. Injury 2008;39(Suppl 2):S37-43
74. Brinker MR, O'Connor DP, Monla YT, Earthman TP. Metabolic and endocrine abnormalities in patients with nonunions. J Orthop Trauma 2007;21:557-70
75. Rodgers MA, Brown JV, Heirs MK, et al. Reporting of industry funded study outcome data: comparison of confidential and published data on the safety and effectiveness of rhBMP-2 for spinal fusion. BMJ 2013;346:f3981